Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 1029-1038

  Kurtzberg, Leslie S ^a   Roth, Stephanie D ^b   Bagley, Rebecca G ^a   Rouleau, Cecile ^a   Yao, Min ^a   Crawford, Jennifer L ^b   Krumbholz, Roy D ^b   Schmid, Steven M ^b   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

Bone marrow CFU GM; Paclitaxel; Tasidotin; Tumor xenografts; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; PACLITAXEL; TASIDOTIN; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER INHIBITION; CANCER MODEL; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MICROTUBULE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; BONE MARROW CELLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA; MALE; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; OLIGOPEPTIDES; PACLITAXEL; PROSTATIC NEOPLASMS; TUBULIN; TUMOR STEM CELL ASSAY; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69049106404     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0959-z     Document Type: Article

References (58)

1. SP Banks-Schlegel AF Gazdar CC Harris 1985 Intermediate filament and cross-linked envelope expression in human lung tumor cell lines Cancer Res 45 1187 1197
2. M Beckwith DL Longo CD O'Connell et al. 1990 Phorbol ester-induced cell cycle-specific growth inhibition of human B-lymphoma cell lines J Natl Cancer Inst 82 501 509
3. J Bennouna JP Delord M Campone et al. 2008 Vinflunine: a new microtubule inhibitor agent Clin Cancer Res 14 1625 1632
4. A Bhagra RD Rao 2007 Chemotherapy-induced neuropathy Curr Oncol Rep 9 290 299
5. KMR Bhat V Setaluri 2007 Microtubule-associated proteins as targets in cancer chemotherapy Clin Cancer Res 13 2849 2854
6. PL Bonate D Beyerlein J Crawford et al. 2007 Pharmacokinetics in mice with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite AAPS J 9 E378 E387
7. Corbett TH, Polin L, Roberts BJ (2002) Transplantable syngeneic rodent tumors. In: Teicher BA et al (eds) Tumor models in cancer research. Humana Press, Totowa, pp 41-71
8. J Cortes J Baselga 2007 Targeting the microtubules in breast cancer beyond taxanes: the epothilones Oncologist 12 271 280
9. C Cunningham LJ Appleman M Kirvan-Visovatti et al. 2005 Phase I and pharmacokinetic study of the dolastatin-15 analog tasidotin (ILX651) administered intravenously on days 1, 3 and 5 every 3 weeks in patients with advanced solid tumors Clin Cancer Res 11 7825 7833
10. S Ebbinghaus E Rubin E Hersh et al. 2005 A phase I study of the dolastatin-15 analog tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors Clin Cancer Res 11 7807 7816
11. C Erickson-Miller 1997 Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro Cancer Chemother Pharmacol 39 467 472
12. T Ferguson N Wilcken R Vagg et al. 2007 Taxanes for adjuvant treatment of early breast cancer Cochrane Database Syst Rev 4 CD004421
13. C Ferlini D Gallo G Scambia 2008 New taxanes in development Exp Opin Invest Drugs 17 335 347
14. V Garg W Zhang P Gidwani et al. 2007 Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma and osteosarcoma Clin Cancer Res 13 5446 5454
15. S Goodin MP Kane EH Rubin 2004 Epothilones: mechanism of action and biologic activity J Clin Oncol 22 2015 2025
16. C Graham C Tucker J Creech et al. 2006 Evaluation of the antitumor efficacy, pharmacokinetics and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo Clin Cancer Res 12 223 234
17. P Guo X Wang F Zhou JM Gallo 2004 Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry J Chromatogr B 809 273 278
18. IC Henderson V Bhatia 2007 Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy Exp Rev Anticancer Ther 7 919 943
19. P Hinnen FA Eskens 2007 Vascular disrupting agents in clinical development Brit J Cancer 96 1159 1165
20. SB Horwitz D Cohen S Rao et al. 1993 Taxol: mechanisms of action and resistance J Natl Cancer Inst Monogr 15 55 61
21. B Hosten C Abbara B Petit et al. 2008 Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice Drug Metab Dispos 36 1729 1735
22. MT Huizing ACF Keung H Rosing et al. 1993 Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients J Clin Oncol 11 2127 2135
23. IS Johnson JG Armstrong M Gorman et al. 1967 The vinca alkaloids: a new class of oncolytic agents Cancer Res 23 1390 1427
24. MA Jordan D Thrower L Wilson 1991 Mechanism of inhibition of cell proliferation by Vinca alkaloids Cancer Res 51 2212 2222
25. MA Jordan L Wilson 2004 Microtubules as a target for anticancer drugs Nat Rev Cancer 4 253 265
26. ME Kaighn KS Narayan Y Ohnuki et al. 1979 Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Investig Urol 17 16 23
27. KK Kaur C Verschraegen 2005 Tasidotin HCl Curr Opin Invest Drugs 6 631 638
28. A Kruczynski JM Barret C Etievant et al. 1998 Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid Biochem Pharmacol 55 635 648
29. A Kruczynski C Etievant D Perrin et al. 2002 Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development Br J Cancer 86 143 150
30. S Kummar M Gutierrez JH Doroshow et al. 2006 Drug development in oncology: classical cytotoxics and molecularly targeted agents Brit J Clin Pharmacol 62 15 26
31. LS Kurtzberg T Battle C Rouleau et al. 2008 Bone marrow and tumor cell CFU and human tumor xenograft efficacy of non-camptothecin and camptothecin topoisomerase I inhibitors Mol Cancer Ther 7 10 3212 3222
32. JJ Lee SM Swain 2008 The epothilones: translating from the laboratory to the clinic Clin Cancer Res 14 1618 1624
33. M Markman 2008 Taxanes in the management of gynecologic malignancies Exp Rev Anticancer Ther 8 219 226
34. N Masubuchi 2004 A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay Clin Cancer Res 10 6722 6731
35. Y Matsuoka GE Moore Y Yagi et al. 1967 Production of free light chains of immunoglobulin by a haematopoietic cell line derived from a patient with multiple myeloma Proc Soc Exp Biol Med 125 1246 1250
36. R Mihelic J Kaufman S Lonial 2007 Maintenance therapy in lymphoma Clin Lymphoma Myeloma 7 507 513
37. AC Mita LA Hammond PL Bonate et al. 2006 Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third generation dolastatin-15 analog, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors Clin Cancer Res 12 5207 5215
38. JH Nettles H Li B Cornett 2004 The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography Science 305 866 869
39. VK Ngan K Bellman BT Hill et al. 2001 Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine Mol Pharmacol 60 225 232
40. VK Ngan K Bellman D Panda et al. 2000 Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules Cancer Res 60 5045 5051
41. AA Ovejera DP Houchens 1981 Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents Sem Oncol 8 386 393
42. Perez EA (2007) Novel enhanced delivery taxanes: an update. Semin Oncol 34:Suppl 1-5
43. A Pessina 2003 Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics Toxicol Sci 75 355 367
44. JK Peterson PJ Houghton 2004 Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development Eur J Cancer 40 837 844
45. J Poncet 1999 The dolastatins, a family of promising antineoplastic agents Curr Pharm Des 5 139 162
46. B Pourroy M Carre S Honore et al. 2004 Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a post mitotic G1 arrest and a mitochondrial pathway Mol Pharmacol 66 580 591
47. A Ray T Okouneva T Manna 2007 Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate Cancer Res 67 3767 3776
48. I Ringel SB Horwitz 1991 Studies with RP56967 (Taxotere): a semisynthetic analog of taxol J Natl Cancer Inst 83 288 291
49. Rowinsky EK, Donehower RC (1996) Antimicrotubule agents. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy. Lippincott-Raven, New York, pp 263-296
50. VS Sethi JC Kimball 1981 Pharmacokinetics of vincristine sulfate in children Cancer Chemother Pharmacol 6 111 115
51. C Simoens JB Vermorken AEC Korst et al. 2006 Cell cycle effects of vinflunine, the most promising Vinca alkaloid and its interaction with radiation in vitro Cancer Chemother Pharmacol 58 210 218
52. A Stierle G Strobel D Stierle 1993 Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew Science 260 214 218
53. TE Stinchcombe 2007 Nanoparticle albumin-bound paclitaxel: a novel cremophor-EL-free formulation of paclitaxel Nanomedicine 2 415 423
54. BA Teicher 2008 Newer cytotoxic agents: attacking cancer broadly Clin Cancer Res 14 1610 1617
55. I Tusquets LG Estevez I Alvarez et al. 2007 The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials Clin Breast Cancer 7 764 774
56. MS Webb P Logan PM Kanter et al. 1998 Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer Cancer Chemother Pharmacol 42 461 470
57. AB Zelnak 2007 Clinical pharmacology and use of microtubule targeting agents in cancer therapy Methods Mol Med 137 209 234
58. C Zwick B Gleissner M Pfreundschuh 2007 Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma Clin Lymphoma Myeloma 8 suppl 2 S43 49